{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T04:30:27Z","timestamp":1728534627295},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-024-04086-6","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T23:02:49Z","timestamp":1716591769000},"page":"3447-3462","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Discovery of a T cell proliferation-associated regulator signature correlates with prognosis risk and immunotherapy response in bladder cancer"],"prefix":"10.1007","volume":"56","author":[{"given":"Ting","family":"Yan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,24]]},"reference":[{"issue":"8","key":"4086_CR1","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1007\/s00345-019-02984-4","volume":"38","author":"A Richters","year":"2020","unstructured":"Richters A, Aben KKH, Kiemeney L (2020) The global burden of urinary bladder cancer: an update. World J Urol 38(8):1895\u20131904. https:\/\/doi.org\/10.1007\/s00345-019-02984-4","journal-title":"World J Urol"},{"issue":"7679","key":"4086_CR2","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1038\/551S34a","volume":"551","author":"C Berdik","year":"2017","unstructured":"Berdik C (2017) Unlocking bladder cancer. Nature 551(7679):S34-s35. https:\/\/doi.org\/10.1038\/551S34a","journal-title":"Nature"},{"key":"4086_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21176271","author":"JC Pardo","year":"2020","unstructured":"Pardo JC, Ruiz de Porras V, Plaja A, Carrato C, Etxaniz O, Buisan O, Font A (2020) Moving towards personalized medicine in muscle-invasive bladder cancer: where are we now and where are we going? Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21176271","journal-title":"Int J Mol Sci"},{"issue":"10","key":"4086_CR4","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41585-019-0226-y","volume":"16","author":"AK Schneider","year":"2019","unstructured":"Schneider AK, Chevalier MF, Derr\u00e9 L (2019) The multifaceted immune regulation of bladder cancer. Nat Rev Urol 16(10):613\u2013630. https:\/\/doi.org\/10.1038\/s41585-019-0226-y","journal-title":"Nat Rev Urol"},{"issue":"2","key":"4086_CR5","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41568-020-00313-1","volume":"21","author":"L Tran","year":"2021","unstructured":"Tran L, Xiao JF, Agarwal N, Duex JE, Theodorescu D (2021) Advances in bladder cancer biology and therapy. Nat Rev Cancer 21(2):104\u2013121. https:\/\/doi.org\/10.1038\/s41568-020-00313-1","journal-title":"Nat Rev Cancer"},{"issue":"7463","key":"4086_CR6","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, B\u00f8rresen-Dale AL, Boyault S, Burkhardt B, Butler AP, Caldas C, Davies HR, Desmedt C, Eils R, Eyfj\u00f6rd JE, Foekens JA, Greaves M, Hosoda F, Hutter B, Ilicic T, Imbeaud S, Imielinski M, J\u00e4ger N, Jones DT, Jones D, Knappskog S, Kool M, Lakhani SR, L\u00f3pez-Ot\u00edn C, Martin S, Munshi NC, Nakamura H, Northcott PA, Pajic M, Papaemmanuil E, Paradiso A, Pearson JV, Puente XS, Raine K, Ramakrishna M, Richardson AL, Richter J, Rosenstiel P, Schlesner M, Schumacher TN, Span PN, Teague JW, Totoki Y, Tutt AN, Vald\u00e9s-Mas R, van Buuren MM, van\u2019t Veer L, Vincent-Salomon A, Waddell N, Yates LR, Zucman-Rossi J, Futreal PA, McDermott U, Lichter P, Meyerson M, Grimmond SM, Siebert R, Campo E, Shibata T, Pfister SM, Campbell PJ, Stratton MR (2013) Signatures of mutational processes in human cancer. Nature 500(7463):415\u2013421. https:\/\/doi.org\/10.1038\/nature12477","journal-title":"Nature"},{"issue":"19","key":"4086_CR7","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1001\/jama.2020.17598","volume":"324","author":"AT Lenis","year":"2020","unstructured":"Lenis AT, Lec PM, Chamie K, Mshs MD (2020) Bladder cancer: a review. JAMA 324(19):1980\u20131991. https:\/\/doi.org\/10.1001\/jama.2020.17598","journal-title":"JAMA"},{"key":"4086_CR8","doi-asserted-by":"publisher","first-page":"100296","DOI":"10.1016\/j.ctarc.2020.100296","volume":"26","author":"LP Rhea","year":"2021","unstructured":"Rhea LP, Mendez-Marti S, Kim D, Aragon-Ching JB (2021) Role of immunotherapy in bladder cancer. Cancer Treat Res Commun 26:100296. https:\/\/doi.org\/10.1016\/j.ctarc.2020.100296","journal-title":"Cancer Treat Res Commun"},{"issue":"11","key":"4086_CR9","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman AD, Fritz JM, Lenardo MJ (2020) A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol 20(11):651\u2013668. https:\/\/doi.org\/10.1038\/s41577-020-0306-5","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"4086_CR10","doi-asserted-by":"publisher","first-page":"e0004","DOI":"10.5041\/rmmj.10179","volume":"6","author":"K Perica","year":"2015","unstructured":"Perica K, Varela JC, Oelke M, Schneck J (2015) Adoptive T cell immunotherapy for cancer. Rambam Maimonides Med J 6(1):e0004. https:\/\/doi.org\/10.5041\/rmmj.10179","journal-title":"Rambam Maimonides Med J"},{"issue":"7","key":"4086_CR11","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/s1470-2045(21)00152-2","volume":"22","author":"T Powles","year":"2021","unstructured":"Powles T, Cs\u0151szi T, \u00d6zg\u00fcro\u011flu M, Matsubara N, G\u00e9czi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Morales Barrera R, Fl\u00e9chon A, Gunduz S, Loriot Y, Rodriguez-Vida A, Mamtani R, Yu EY, Nam K, Imai K, Homet Moreno B, Alva A (2021) Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol 22(7):931\u2013945. https:\/\/doi.org\/10.1016\/s1470-2045(21)00152-2","journal-title":"Lancet Oncol"},{"issue":"22","key":"4086_CR12","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, Bamias A, Lebret T, Shariat SF, Park SH, Ye D, Agerbaek M, Enting D, McDermott R, Gajate P, Peer A, Milowsky MI, Nosov A, Neif Antonio J Jr, Tupikowski K, Toms L, Fischer BS, Qureshi A, Collette S, Unsal-Kacmaz K, Broughton E, Zardavas D, Koon HB, Galsky MD (2021) Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med 384(22):2102\u20132114. https:\/\/doi.org\/10.1056\/NEJMoa2034442","journal-title":"N Engl J Med"},{"key":"4086_CR13","doi-asserted-by":"publisher","first-page":"970949","DOI":"10.3389\/fimmu.2022.970949","volume":"13","author":"J Hou","year":"2022","unstructured":"Hou J, Wen X, Lu Z, Wu G, Yang G, Tang C, Qu G, Xu Y (2022) A novel T-cell proliferation-associated regulator signature pre-operatively predicted the prognostic of bladder cancer. Front Immunol 13:970949. https:\/\/doi.org\/10.3389\/fimmu.2022.970949","journal-title":"Front Immunol"},{"issue":"11","key":"4086_CR14","doi-asserted-by":"publisher","first-page":"5365","DOI":"10.7150\/thno.58390","volume":"11","author":"YT Liu","year":"2021","unstructured":"Liu YT, Sun ZJ (2021) Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics 11(11):5365\u20135386. https:\/\/doi.org\/10.7150\/thno.58390","journal-title":"Theranostics"},{"issue":"7902","key":"4086_CR15","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/s41586-022-04494-7","volume":"603","author":"M Legut","year":"2022","unstructured":"Legut M, Gajic Z, Guarino M, Daniloski Z, Rahman JA, Xue X, Lu C, Lu L, Mimitou EP, Hao S, Davoli T, Diefenbach C, Smibert P, Sanjana NE (2022) A genome-scale screen for synthetic drivers of T cell proliferation. Nature 603(7902):728\u2013735. https:\/\/doi.org\/10.1038\/s41586-022-04494-7","journal-title":"Nature"},{"issue":"10","key":"4086_CR16","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, Li Z, Traugh N, Bu X, Li B, Liu J, Freeman GJ, Brown MA, Wucherpfennig KW, Liu XS (2018) Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med 24(10):1550\u20131558. https:\/\/doi.org\/10.1038\/s41591-018-0136-1","journal-title":"Nat Med"},{"key":"4086_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/cells11030357","author":"A Audisio","year":"2022","unstructured":"Audisio A, Buttigliero C, Delcuratolo MD, Parlagreco E, Audisio M, Ungaro A, Di Stefano RF, Di Prima L, Turco F, Tucci M (2022) New perspectives in the medical treatment of non-muscle-invasive bladder cancer: immune checkpoint inhibitors and beyond. Cells. https:\/\/doi.org\/10.3390\/cells11030357","journal-title":"Cells"},{"issue":"34","key":"4086_CR18","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1200\/jco.2014.57.5548","volume":"32","author":"RH Mak","year":"2014","unstructured":"Mak RH, Hunt D, Shipley WU, Efstathiou JA, Tester WJ, Hagan MP, Kaufman DS, Heney NM, Zietman AL (2014) Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of radiation therapy oncology group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clini Oncol Off J Am Soc Clin Oncol 32(34):3801\u20133809. https:\/\/doi.org\/10.1200\/jco.2014.57.5548","journal-title":"J Clini Oncol Off J Am Soc Clin Oncol"},{"issue":"4","key":"4086_CR19","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.euf.2020.01.007","volume":"6","author":"G Gakis","year":"2020","unstructured":"Gakis G (2020) Management of muscle-invasive bladder cancer in the 2020s: challenges and perspectives. Eur Urol Focus 6(4):632\u2013638. https:\/\/doi.org\/10.1016\/j.euf.2020.01.007","journal-title":"Eur Urol Focus"},{"issue":"8","key":"4086_CR20","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1080\/08820139.2022.2118606","volume":"51","author":"DF Ward Grados","year":"2022","unstructured":"Ward Grados DF, Ahmadi H, Griffith TS, Warlick CA (2022) Immunotherapy for bladder cancer: latest advances and ongoing clinical trials. Immunol Invest 51(8):2226\u20132251. https:\/\/doi.org\/10.1080\/08820139.2022.2118606","journal-title":"Immunol Invest"},{"key":"4086_CR21","doi-asserted-by":"publisher","first-page":"844142","DOI":"10.3389\/fimmu.2022.844142","volume":"13","author":"B Lv","year":"2022","unstructured":"Lv B, Wang Y, Ma D, Cheng W, Liu J, Yong T, Chen H, Wang C (2022) Immunotherapy: reshape the tumor immune microenvironment. Front Immunol 13:844142. https:\/\/doi.org\/10.3389\/fimmu.2022.844142","journal-title":"Front Immunol"},{"issue":"12","key":"4086_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","volume":"50","author":"P Darvin","year":"2018","unstructured":"Darvin P, Toor SM, Sasidharan Nair V, Elkord E (2018) Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med 50(12):1\u201311. https:\/\/doi.org\/10.1038\/s12276-018-0191-1","journal-title":"Exp Mol Med"},{"issue":"5795","key":"4086_CR23","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1126\/science.1129139","volume":"313","author":"J Galon","year":"2006","unstructured":"Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pag\u00e8s C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohou\u00e9 F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pag\u00e8s F (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795):1960\u20131964. https:\/\/doi.org\/10.1126\/science.1129139","journal-title":"Science"},{"issue":"3","key":"4086_CR24","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon J, Bruni D (2019) Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discovery 18(3):197\u2013218. https:\/\/doi.org\/10.1038\/s41573-018-0007-y","journal-title":"Nat Rev Drug Discovery"},{"key":"4086_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/medicina56010015","author":"B Arneth","year":"2019","unstructured":"Arneth B (2019) Tumor microenvironment. Medicina (Kaunas). https:\/\/doi.org\/10.3390\/medicina56010015","journal-title":"Medicina (Kaunas)"},{"issue":"4","key":"4086_CR26","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.immuni.2013.10.003","volume":"39","author":"G Bindea","year":"2013","unstructured":"Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Angell H, Fredriksen T, Lafontaine L, Berger A, Bruneval P, Fridman WH, Becker C, Pag\u00e8s F, Speicher MR, Trajanoski Z, Galon J (2013) Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39(4):782\u2013795. https:\/\/doi.org\/10.1016\/j.immuni.2013.10.003","journal-title":"Immunity"},{"issue":"7","key":"4086_CR27","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s12272-019-01143-y","volume":"42","author":"N Kim","year":"2019","unstructured":"Kim N, Lee HH, Lee HJ, Choi WS, Lee J, Kim HS (2019) Natural killer cells as a promising therapeutic target for cancer immunotherapy. Arch Pharm Res 42(7):591\u2013606. https:\/\/doi.org\/10.1007\/s12272-019-01143-y","journal-title":"Arch Pharm Res"},{"issue":"1","key":"4086_CR28","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12943-020-01238-x","volume":"19","author":"SY Wu","year":"2020","unstructured":"Wu SY, Fu T, Jiang YZ, Shao ZM (2020) Natural killer cells in cancer biology and therapy. Mol Cancer 19(1):120. https:\/\/doi.org\/10.1186\/s12943-020-01238-x","journal-title":"Mol Cancer"},{"issue":"1","key":"4086_CR29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","volume":"20","author":"SK Wculek","year":"2020","unstructured":"Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D (2020) Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol 20(1):7\u201324. https:\/\/doi.org\/10.1038\/s41577-019-0210-z","journal-title":"Nat Rev Immunol"},{"key":"4086_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13081946","author":"E Cendrowicz","year":"2021","unstructured":"Cendrowicz E, Sas Z, Bremer E, Rygiel TP (2021) The role of macrophages in cancer development and therapy. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13081946","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4086_CR31","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12929-022-00866-3","volume":"29","author":"A Tiwari","year":"2022","unstructured":"Tiwari A, Trivedi R, Lin SY (2022) Tumor microenvironment: barrier or opportunity towards effective cancer therapy. J Biomed Sci 29(1):83. https:\/\/doi.org\/10.1186\/s12929-022-00866-3","journal-title":"J Biomed Sci"},{"issue":"1","key":"4086_CR32","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1158\/2326-6066.Cir-20-0527","volume":"9","author":"JP V\u00e4yrynen","year":"2021","unstructured":"V\u00e4yrynen JP, Haruki K, Lau MC, V\u00e4yrynen SA, Zhong R, Dias Costa A, Borowsky J, Zhao M, Fujiyoshi K, Arima K, Twombly TS, Kishikawa J, Gu S, Aminmozaffari S, Shi S, Baba Y, Akimoto N, Ugai T, Da Silva A, Guerriero JL, Song M, Wu K, Chan AT, Nishihara R, Fuchs CS, Meyerhardt JA, Giannakis M, Ogino S, Nowak JA (2021) The Prognostic role of macrophage polarization in the colorectal cancer microenvironment. Cancer Immunol Res 9(1):8\u201319. https:\/\/doi.org\/10.1158\/2326-6066.Cir-20-0527","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"4086_CR33","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1111\/cas.14328","volume":"111","author":"K Yamamoto","year":"2020","unstructured":"Yamamoto K, Makino T, Sato E, Noma T, Urakawa S, Takeoka T, Yamashita K, Saito T, Tanaka K, Takahashi T, Kurokawa Y, Yamasaki M, Nakajima K, Mori M, Doki Y, Wada H (2020) Tumor-infiltrating M2 macrophage in pretreatment biopsy sample predicts response to chemotherapy and survival in esophageal cancer. Cancer Sci 111(4):1103\u20131112. https:\/\/doi.org\/10.1111\/cas.14328","journal-title":"Cancer Sci"},{"issue":"2","key":"4086_CR34","doi-asserted-by":"publisher","first-page":"581","DOI":"10.3892\/or.2019.7196","volume":"42","author":"Y Xue","year":"2019","unstructured":"Xue Y, Tong L, LiuAnwei Liu F, Liu A, Zeng S, Xiong Q, Yang Z, He X, Sun Y, Xu C (2019) Tumor-infiltrating M2 macrophages driven by specific genomic alterations are associated with prognosis in bladder cancer. Oncol Rep 42(2):581\u2013594. https:\/\/doi.org\/10.3892\/or.2019.7196","journal-title":"Oncol Rep"},{"issue":"1","key":"4086_CR35","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/cr.2016.151","volume":"27","author":"A Tanaka","year":"2017","unstructured":"Tanaka A, Sakaguchi S (2017) Regulatory T cells in cancer immunotherapy. Cell Res 27(1):109\u2013118. https:\/\/doi.org\/10.1038\/cr.2016.151","journal-title":"Cell Res"},{"issue":"11","key":"4086_CR36","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.trecan.2022.06.008","volume":"8","author":"F Shan","year":"2022","unstructured":"Shan F, Somasundaram A, Bruno TC, Workman CJ, Vignali DAA (2022) Therapeutic targeting of regulatory T cells in cancer. Trends in cancer 8(11):944\u2013961. https:\/\/doi.org\/10.1016\/j.trecan.2022.06.008","journal-title":"Trends in cancer"},{"key":"4086_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18102186","author":"M Miyake","year":"2017","unstructured":"Miyake M, Tatsumi Y, Gotoh D, Ohnishi S, Owari T, Iida K, Ohnishi K, Hori S, Morizawa Y, Itami Y, Nakai Y, Inoue T, Anai S, Torimoto K, Aoki K, Shimada K, Konishi N, Tanaka N, Fujimoto K (2017) Regulatory T cells and tumor-associated macrophages in the tumor microenvironment in non-muscle invasive bladder cancer treated with intravesical bacille calmette-gu\u00e9rin: a long-term follow-up study of a Japanese cohort. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms18102186","journal-title":"Int J Mol Sci"},{"issue":"4","key":"4086_CR38","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.trecan.2022.12.007","volume":"9","author":"N Guti\u00e9rrez-Melo","year":"2023","unstructured":"Guti\u00e9rrez-Melo N, Baumjohann D (2023) T follicular helper cells in cancer. Trends in cancer 9(4):309\u2013325. https:\/\/doi.org\/10.1016\/j.trecan.2022.12.007","journal-title":"Trends in cancer"},{"issue":"6","key":"4086_CR39","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","volume":"6","author":"C Dolladille","year":"2020","unstructured":"Dolladille C, Ederhy S, Sassier M, Cautela J, Thuny F, Cohen AA, Fedrizzi S, Chr\u00e9tien B, Da-Silva A, Plane AF, Legallois D, Milliez PU, Lelong-Boulouard V, Alexandre J (2020) Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol 6(6):865\u2013871. https:\/\/doi.org\/10.1001\/jamaoncol.2020.0726","journal-title":"JAMA Oncol"},{"issue":"9","key":"4086_CR40","doi-asserted-by":"publisher","first-page":"e2002104","DOI":"10.1002\/adhm.202002104","volume":"10","author":"M He","year":"2021","unstructured":"He M, Yang T, Wang Y, Wang M, Chen X, Ding D, Zheng Y, Chen H (2021) Immune checkpoint inhibitor-based strategies for synergistic cancer therapy. Adv Healthcare Mater 10(9):e2002104. https:\/\/doi.org\/10.1002\/adhm.202002104","journal-title":"Adv Healthcare Mater"},{"issue":"2","key":"4086_CR41","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","volume":"39","author":"DL Jardim","year":"2021","unstructured":"Jardim DL, Goodman A, de Melo GD, Kurzrock R (2021) The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell 39(2):154\u2013173. https:\/\/doi.org\/10.1016\/j.ccell.2020.10.001","journal-title":"Cancer Cell"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-024-04086-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-024-04086-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-024-04086-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T16:03:34Z","timestamp":1728489814000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-024-04086-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,24]]},"references-count":41,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["4086"],"URL":"https:\/\/doi.org\/10.1007\/s11255-024-04086-6","relation":{},"ISSN":["1573-2584"],"issn-type":[{"type":"electronic","value":"1573-2584"}],"subject":[],"published":{"date-parts":[[2024,5,24]]},"assertion":[{"value":"23 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}